Key result
An ERAS pathway with pregabalin and ketorolac significantly reduced length of hospital stay by 10% and morphine dose equivalents by 40% compared with standard of care plus placebo.
Why the study?
Opioid exposure is a concern after live kidney donation, and it was unknown whether an ERAS pathway with ketorolac and pregabalin could decrease narcotic use without increasing complications compared with standard of care.
Does an ERAS pathway with pregabalin and ketorolac reduce narcotic use and length of stay in patients undergoing live donor nephrectomy compared with standard of care plus placebo?
RCT (n=62)
Double-blind
randomized
No
Does an ERAS pathway with pregabalin and ketorolac reduce narcotic use and length of stay in patients undergoing live donor nephrectomy compared with standard of care plus placebo?
An ERAS pathway utilizing pregabalin and ketorolac significantly reduces opioid requirements and length of hospital stay in patients undergoing live donor nephrectomy.
Answers are grounded in this paper and cite their sources.
Supports nonopioid ERAS for living kidney donors; extends RCT evidence on opioid reduction to donor nephrectomy.
Opioid exposure is a concern after live donation for kidney transplant. We theorized that an enhanced recovery after surgery pathway (ERAS) using pregabalin preoperatively to desensitize nerves followed by the nonsteroidal anti-inflammatory drug ketorolac, during and after surgery, can control pain, thus requiring less perioperative narcotics. The aim of this study was to determine if the use of a nonopioid analgesic ERAS protocol for donor nephrectomies could decrease the use of narcotics without an increase in complications compared with standard of care (SOC). This is a single-center, prospective, double-blind, randomized clinical trial involving a total of 62 patients undergoing nephrectomy for live donor kidney transplant. Length of hospital stay (LOS) was significantly reduced by 10% in the ERAS group versus the SOC-plus-placebo group. Morphine dose equivalents were significantly reduced by 40% in the study group versus the SOC-plus-placebo group. The use of this nonopioid analgesic ERAS pathway for donor nephrectomies decreased the use of narcotics without an increase in complications compared with SOC. There was significantly reduced LOS and less narcotic use in the study group versus the SOC-plus-placebo group. (ClinicalTrials.gov registration number: NCT03669081). Opioid exposure is a concern after live donation for kidney transplant. We theorized that an enhanced recovery after surgery pathway (ERAS) using pregabalin preoperatively to desensitize nerves followed by the nonsteroidal anti-inflammatory drug ketorolac, during and after surgery, can control pain, thus requiring less perioperative narcotics. The aim of this study was to determine if the use of a nonopioid analgesic ERAS protocol for donor nephrectomies could decrease the use of narcotics without an increase in complications compared with standard of care (SOC). This is a single-center, prospective, double-blind, randomized clinical trial involving a total of 62 patients undergoing nephrectomy for live donor kidney transplant. Length of hospital stay (LOS) was significantly reduced by 10% in the ERAS group versus the SOC-plus-placebo group. Morphine dose equivalents were significantly reduced by 40% in the study group versus the SOC-plus-placebo group. The use of this nonopioid analgesic ERAS pathway for donor nephrectomies decreased the use of narcotics without an increase in complications compared with SOC. There was significantly reduced LOS and less narcotic use in the study group versus the SOC-plus-placebo group. (ClinicalTrials.gov registration number: NCT03669081).
No takes yet. Share an insight, caveat, or question.
Campsen et al. (2018) conducted an RCT in Live donor kidney transplant (n=62). ERAS pathway with pregabalin and ketorolac vs. Standard of care plus placebo was evaluated on Morphine dose equivalents and length of hospital stay. An ERAS pathway with pregabalin and ketorolac significantly reduced length of hospital stay by 10% and morphine dose equivalents by 40% compared with standard of care plus placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: